search
Back to results

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial

Primary Purpose

Coronary Artery Disease, Heart Failure Systolic

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Revascularization by PCI
Revascularization by CABG
Sponsored by
Sunnybrook Health Sciences Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring Left ventricular dysfunction, CABG, PCI, MACCE

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age >18 years;
  2. LVEF ≤40% quantified by either echocardiography, SPECT ventriculography, or magnetic resonance within 2 months of randomization;
  3. Prognostically important multivessel CAD (triple vessel CAD or double vessel disease including the left anterior descending (LAD) or LM). Significant coronary stenosis is defined as ≥ 70% based on coronary angiography, and/or fractional flow reserve (FFR) ≤0.80 or instantaneous wave-free ratio (iFR) ≤0.89. For LM disease, significant coronary stenosis is defined as >50% based on coronary angiography, intravascular ultrasound (IVUS) minimal luminal area (MLA) ≤6.0 mm2 (<4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements;
  4. The institutional Heart Team agrees that guideline-directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization.

Exclusion Criteria:

  1. Decompensated HF requiring inotropic/adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ventricular assist device therapy less than 48 hours prior to randomization;
  2. Recent (<4 weeks) ST-elevation MI;
  3. Concomitant severe valvular disease or other condition such as left ventricular aneurysm requiring surgical repair or replacement;
  4. Planned major concomitant surgical procedures (LAAO and AF ablation surgical procedures permitted);
  5. Prior PCI within the past 12 months (to reduce restenosis events from prior PCIs contributing to the primary outcome);
  6. Prior cardiac surgery;
  7. Prohibitive bleeding risk mandating avoidance of dual antiplatelet therapy;
  8. Circumstances likely to lead to poor treatment adherence;
  9. Severe end-organ dysfunction (such as dialysis, liver failure, respiratory failure, cancer) that reduces life expectancy to less than 5 years;
  10. Current pregnancy;
  11. Patient not amenable to both CABG or PCI according to the Heart Team.
  12. Failure to provide informed consent.

Sites / Locations

  • University of Calgary; Libin Cardiovascular InstituteRecruiting
  • Fraser Health; Royal Columbian HospitalRecruiting
  • London Health Sciences Center, University HospitalRecruiting
  • Southlake Regional HCRecruiting
  • Sunnybrook Health Sciences CenterRecruiting
  • Montreal Heart InstituteRecruiting
  • Jilin Heart HospitalRecruiting
  • Clinical Hospital DubravaRecruiting
  • G Kuppuswamy Naidu Memorial Hospital (GKNM)Recruiting
  • European Hospital, Via PortuenseRecruiting
  • Hospital del VinalopóRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Revascularization by PCI

Revascularization by CABG

Arm Description

Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter >2.0 mm for PCI. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon.

Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter >1.5 mm for CABG. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon

Outcomes

Primary Outcome Measures

The Primary outcome is a Composite of all-cause mortality, stroke, spontaneous myocardial infarction, urgent repeat revascularization or heart failure readmission.
Time to event outcome measured as the time from randomization to the occurence of the first event.

Secondary Outcome Measures

Death
Death will be reported at 30 days. Death over the entire duration of study will be reported as a time to event outcome. Death will be adjudicated as cardiovascular, non-cardiovascular and unknown.
Myocardial Infarction (MI)
Periprocedural/perioperative MI is defined as <48 hours from revascularization. Spontaneous MI is defined as > or = 48 hours post revascularization
Number of participants with Stroke
Strokes will be classified as ischemic, hemorrhagic or uncertain.
Repeat Revascularization (RR)
Only urgent clinically driven unplanned repeat revascularizations by either PCI or CABG count towards primary ouctome. RR will be classified according to type (CABG vs. PCI), by location (target vessel vs. target lesion vs. graft vs. other), and whether clinically vs. non-clinically driven. Stent thrombosis (ARC defined) and graft thrombosis/ occlusion will be reported.
Hospitalizations
Hospitalizations will be defined as cardiac or non-cardiac. Hospitalizations will be reported as the number of participants with hospitalizations and as a count.
Composite of death/stroke/spontaneous MI
Measured as a time-to-event.
Composite of death/stroke/spontaneous MI/RR
Measured as a time-to-event.
Composite of death or cardiac hospitalization
Measured as a time-to-event.
Coronary composite endpoint
Coronary heart disease death, non-fatal MI, and coronary revascularization procedure. Measured as time-to-event outcome.
Heart Failure endpoint
Heart Failure Event (composite of heart failure death, heart failure hospitalization or revascularization for HF). Measured as time-to-event outcome.
Hierarchal Heart Failure outcome
The key hierarchal outcome of time to death and frequency of HF rehospitalizations will be tested using a win ratio
Number of participants with advanced Heart failure therapies
This includes - ICD/CRT implantation,Mitral valve repair (transcatheter/surgical),Ventricular Assist Device and Heart Transplant
Major Adverse Events
These will be reported as the composite and individually: new renal replacement therapy, major bleeding (Bleeding Academic Research Consortium (BARC) 3-5), major vascular complication (according to VARC-2 criteria), unplanned RR, other reoperation, surgical site complication, intubation >48 hours, cardiac arrest, advanced cardiac life support, stroke and death.

Full Information

First Posted
June 8, 2022
Last Updated
October 16, 2023
Sponsor
Sunnybrook Health Sciences Centre
Collaborators
Canadian Institutes of Health Research (CIHR), Weill Medical College of Cornell University
search

1. Study Identification

Unique Protocol Identification Number
NCT05427370
Brief Title
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial
Official Title
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 22, 2023 (Actual)
Primary Completion Date
April 2029 (Anticipated)
Study Completion Date
December 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sunnybrook Health Sciences Centre
Collaborators
Canadian Institutes of Health Research (CIHR), Weill Medical College of Cornell University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
Detailed Description
The evidence comparing PCI and CABG with medical therapy in patients with iLVSD has been the subject of multiple systematic reviews/meta-analyses of observational studies with inconsistent results. There is a current lack of evidence from properly powered randomized trials comparing contemporary state-of-the-art PCI vs. CABG to guide the clinical management in the vulnerable population of patients with iLVSD. Understanding the relative impact of both revascularization strategies on clinical outcomes in this prevalent population would have important clinical implications. The overarching aim of the STICH3C trial is to compare the clinical efficacy and safety of contemporary PCI and CABG to treat patients with multivessel/left main (LM) CAD and iLVSD. Participants will be allocated in a 1:1 ratio to either study arm using permuted block randomization stratified for study center and acute coronary syndrome (ACS) presentation through a centrally controlled, automated, web system. Eligible patients who provide informed consent can be enrolled. It is expected that initial revascularization will take place within 2 weeks of randomization. Staged PCI is expected to take place within 90 days of randomization. The recruitment will occur over 3 years, with a total study duration of 7 years, and a median duration of follow-up of 5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Heart Failure Systolic
Keywords
Left ventricular dysfunction, CABG, PCI, MACCE

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The STICH3C trial is a prospective, unblinded, international multi-center randomized trial of comparing revascularization by PCI vs. CABG in patients with multivessel/LM CAD and reduced LVEF.
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
754 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Revascularization by PCI
Arm Type
Experimental
Arm Description
Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter >2.0 mm for PCI. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon.
Arm Title
Revascularization by CABG
Arm Type
Experimental
Arm Description
Revascularization will be attempted on/for significant lesions in major coronary vessels/side branches as planned by the local Heart Team, with the general recommendation of stenotic/occluded vessels with diameter >1.5 mm for CABG. The Heart Team consists of a minimum of one heart failure cardiologist, one interventional cardiologist and one cardiac surgeon
Intervention Type
Procedure
Intervention Name(s)
Revascularization by PCI
Intervention Description
Contemporary, "State-of-the-art" PCI techniques will be encouraged in STICH3C, based on the most recent evidence and clinical practice guidelines recommendations. The best practices to be followed include the use of physiological and intravascular guidance, new-generation drug-eluting stents or scaffolds, rotational or orbital atherectomy for extensive calcifications, recommended bifurcation techniques, chronic total occlusion for viable segments by experienced operators, and trans-radial access.Planned temporary ventricular support is permitted by experienced operators when deemed indicated.
Intervention Type
Procedure
Intervention Name(s)
Revascularization by CABG
Intervention Description
The surgical revascularization strategy will be tailored according to the individual patient's coronary anatomy, left ventricular remodeling, aortic atherosclerosis, co-morbidities, local expertise, and surgical judgement. An internal thoracic artery will be used to graft the left anterior descending in all cases. Multi-arterial grafting may be considered in patients without significant co-morbidities and with expected limited vasopressor use, or in patients without saphenous conduits. Choice of on- vs. off-pump surgery is influenced by LV size, associated valvular disease, and aortic atherosclerosis, as well as surgeon experience, but on-pump surgery is recommended routinely. The use of adjunctive intra-aortic balloon support or other cardiac support is not routinely recommended in stable patients; the intra-aortic balloon support is the first line mechanical support.
Primary Outcome Measure Information:
Title
The Primary outcome is a Composite of all-cause mortality, stroke, spontaneous myocardial infarction, urgent repeat revascularization or heart failure readmission.
Description
Time to event outcome measured as the time from randomization to the occurence of the first event.
Time Frame
Median follow-up of 5 years.
Secondary Outcome Measure Information:
Title
Death
Description
Death will be reported at 30 days. Death over the entire duration of study will be reported as a time to event outcome. Death will be adjudicated as cardiovascular, non-cardiovascular and unknown.
Time Frame
At 30 days , 90 days and through study completion with a median follow-up of 5 years.
Title
Myocardial Infarction (MI)
Description
Periprocedural/perioperative MI is defined as <48 hours from revascularization. Spontaneous MI is defined as > or = 48 hours post revascularization
Time Frame
At 30 days and through study completion with a median follow-up of 5 years.
Title
Number of participants with Stroke
Description
Strokes will be classified as ischemic, hemorrhagic or uncertain.
Time Frame
At 30 days , 90 days and through study completion with a median follow-up of 5 years.
Title
Repeat Revascularization (RR)
Description
Only urgent clinically driven unplanned repeat revascularizations by either PCI or CABG count towards primary ouctome. RR will be classified according to type (CABG vs. PCI), by location (target vessel vs. target lesion vs. graft vs. other), and whether clinically vs. non-clinically driven. Stent thrombosis (ARC defined) and graft thrombosis/ occlusion will be reported.
Time Frame
At 30 days , 90 days and through study completion with a median follow-up of 5 years.
Title
Hospitalizations
Description
Hospitalizations will be defined as cardiac or non-cardiac. Hospitalizations will be reported as the number of participants with hospitalizations and as a count.
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Composite of death/stroke/spontaneous MI
Description
Measured as a time-to-event.
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Composite of death/stroke/spontaneous MI/RR
Description
Measured as a time-to-event.
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Composite of death or cardiac hospitalization
Description
Measured as a time-to-event.
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Coronary composite endpoint
Description
Coronary heart disease death, non-fatal MI, and coronary revascularization procedure. Measured as time-to-event outcome.
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Heart Failure endpoint
Description
Heart Failure Event (composite of heart failure death, heart failure hospitalization or revascularization for HF). Measured as time-to-event outcome.
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Hierarchal Heart Failure outcome
Description
The key hierarchal outcome of time to death and frequency of HF rehospitalizations will be tested using a win ratio
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Number of participants with advanced Heart failure therapies
Description
This includes - ICD/CRT implantation,Mitral valve repair (transcatheter/surgical),Ventricular Assist Device and Heart Transplant
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Major Adverse Events
Description
These will be reported as the composite and individually: new renal replacement therapy, major bleeding (Bleeding Academic Research Consortium (BARC) 3-5), major vascular complication (according to VARC-2 criteria), unplanned RR, other reoperation, surgical site complication, intubation >48 hours, cardiac arrest, advanced cardiac life support, stroke and death.
Time Frame
Results will be reported at 30 days and 90 days after index procedure (and 30 days after any planned staged PCI, allowed up to 90 days after randomization) as cardiac surgical hospitalizations maybe prolonged.
Other Pre-specified Outcome Measures:
Title
Kansas City Cardiomyopathy Questionnaire-12
Description
The scores range from 0-100 with higher scores indicating higher quality of life. The scores are classified as 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent.
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Seattle Angina Questionnaire-7
Description
It generates a summary score (scale 0-100, 100 = full health, 0 = worst health).
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Short Form 12 Questionnaire
Description
Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time Frame
Through study completion with a median follow-up of 5 years.
Title
EuroQol-5D (EQ-5D)
Description
Each dimension in the EQ-5D-5L has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). The EQ-5D index score is anchored at 1 (full health) and 0 (death).
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Montreal Cognitive Assessment (MoCA)
Description
Scores on the MoCA range from 0-30; a score of 26 or above is considered normal with higher scores indicating higher cognitive function.
Time Frame
Through study completion with a median follow-up of 5 years.
Title
Composite of severe stroke/ventilator dependance/new onset or worsening heart failure/ nursing home admission/ or new onset dialysis
Description
It will be measured as a time to event outcome.
Time Frame
Reported at 1 and 5 years and as a cumulative incidence.
Title
Composite of stroke, nursing home admission and 3 or more non-elective admissions per 12 months
Description
It will be measured as a time to event outcome.
Time Frame
Reported at 1 and 5 years and as a cumulative incidence.
Title
Length of stay outcomes
Description
Length of stay of index ICU admission, Length of hospital stay of index admission. Days alive and out of hospital (DAOH).
Time Frame
Reported at 90 days, 1 year and 5 years - this is only for DAOH.
Title
Cumulative costs
Description
Cumulative costs will be collected over 4 years.
Time Frame
4 years.
Title
Cost-effectiveness
Description
Quality adjusted life years over four years based on EQ-5D at each follow-up time point and four-year cumulative costs.
Time Frame
4 years.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >18 years; LVEF ≤40% quantified by either echocardiography, SPECT ventriculography, or magnetic resonance within 2 months of randomization; Prognostically important multivessel CAD (triple vessel CAD or double vessel disease including the left anterior descending (LAD) or LM). Significant coronary stenosis is defined as ≥ 70% based on coronary angiography, and/or fractional flow reserve (FFR) ≤0.80 or instantaneous wave-free ratio (iFR) ≤0.89. For LM disease, significant coronary stenosis is defined as >50% based on coronary angiography, intravascular ultrasound (IVUS) minimal luminal area (MLA) ≤6.0 mm2 (<4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements; The institutional Heart Team agrees that guideline-directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization. Exclusion Criteria: Decompensated HF requiring inotropic/adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ventricular assist device therapy less than 48 hours prior to randomization; Recent (<4 weeks) ST-elevation MI; Concomitant severe valvular disease or other condition such as left ventricular aneurysm requiring surgical repair or replacement; Planned major concomitant surgical procedures (LAAO and AF ablation surgical procedures permitted); Prior PCI within the past 12 months (to reduce restenosis events from prior PCIs contributing to the primary outcome); Prior cardiac surgery; Prohibitive bleeding risk mandating avoidance of dual antiplatelet therapy; Circumstances likely to lead to poor treatment adherence; Severe end-organ dysfunction (such as dialysis, liver failure, respiratory failure, cancer) that reduces life expectancy to less than 5 years; Current pregnancy; Patient not amenable to both CABG or PCI according to the Heart Team; Takotsubo/Takotsubo Cardiomyopathy/Broken Heart Syndrome; Failure to provide informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stephen Fremes, MD,MSc,FRCSC
Phone
416-480-6100
Ext
6073
Email
stephen.fremes@sunnybrook.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Reena Karkhanis, MBBS,DA,MSc
Phone
416-480-6100
Ext
6086
Email
reena.karkhanis@sunnybrook.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephen Fremes, MD,MSc,FRCSC
Organizational Affiliation
Sunnybrook Health Sciences Center, Toronto, Canada
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Calgary; Libin Cardiovascular Institute
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 4Z6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Robert Miller
First Name & Middle Initial & Last Name & Degree
Imtiaz Ali
First Name & Middle Initial & Last Name & Degree
Bryan Har
First Name & Middle Initial & Last Name & Degree
Jonathan Howlett
First Name & Middle Initial & Last Name & Degree
Nowell Fine
Facility Name
Fraser Health; Royal Columbian Hospital
City
New Westminster
State/Province
British Columbia
ZIP/Postal Code
V3L3W7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Wong
First Name & Middle Initial & Last Name & Degree
Michael Diamant
First Name & Middle Initial & Last Name & Degree
Albert Chan
Facility Name
London Health Sciences Center, University Hospital
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Nagpal
First Name & Middle Initial & Last Name & Degree
Michael Chu
First Name & Middle Initial & Last Name & Degree
Pallav Garg
Facility Name
Southlake Regional HC
City
Newmarket
State/Province
Ontario
ZIP/Postal Code
L3Y 2P9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liane Porepa
First Name & Middle Initial & Last Name & Degree
Christopher Overgard
First Name & Middle Initial & Last Name & Degree
Charles Peniston
Facility Name
Sunnybrook Health Sciences Center
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen Fremes, MD,FRCS(C)
Phone
1-416-480-6100
Ext
66073
First Name & Middle Initial & Last Name & Degree
Dennis Ko
First Name & Middle Initial & Last Name & Degree
Stephanie Poon
Facility Name
Montreal Heart Institute
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H1T 1C8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gilbert Gosselin
Phone
514-376-3330
Ext
3238
First Name & Middle Initial & Last Name & Degree
Jean-Lucien Rouleau
First Name & Middle Initial & Last Name & Degree
Pierre-Emmanuel Noly
First Name & Middle Initial & Last Name & Degree
Jean-Francois Tanguay
First Name & Middle Initial & Last Name & Degree
Guillaume Maquis-Gravel
First Name & Middle Initial & Last Name & Degree
Robert Avram
First Name & Middle Initial & Last Name & Degree
Normand Racine
First Name & Middle Initial & Last Name & Degree
Eileen O'Meara
First Name & Middle Initial & Last Name & Degree
Anique Ducharme
First Name & Middle Initial & Last Name & Degree
Nadia Bouabdallaoui
First Name & Middle Initial & Last Name & Degree
Christine Henri
First Name & Middle Initial & Last Name & Degree
Maxime Tremblay-Gravel
Facility Name
Jilin Heart Hospital
City
Jilin
State/Province
Changchun
ZIP/Postal Code
130117
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Massimo Lemma
First Name & Middle Initial & Last Name & Degree
Francesco Lavarra
Facility Name
Clinical Hospital Dubrava
City
Sušak
State/Province
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Igor Rudez
First Name & Middle Initial & Last Name & Degree
Davor Baric
First Name & Middle Initial & Last Name & Degree
Daniel Unic
First Name & Middle Initial & Last Name & Degree
Josip Varvodic
First Name & Middle Initial & Last Name & Degree
Marko Kusurin
First Name & Middle Initial & Last Name & Degree
Sime Manola
First Name & Middle Initial & Last Name & Degree
Nikola Pavlovic
First Name & Middle Initial & Last Name & Degree
Mario Udovicic
Facility Name
G Kuppuswamy Naidu Memorial Hospital (GKNM)
City
Palayam
State/Province
Tamil Nadu
ZIP/Postal Code
641037
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chandrasekar Padmanabhan
First Name & Middle Initial & Last Name & Degree
Rajpal Abhaichand
First Name & Middle Initial & Last Name & Degree
Shanmuga Sundaram
Facility Name
European Hospital, Via Portuense
City
Roma
State/Province
RM
ZIP/Postal Code
00149
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruggero De Paulis
Phone
39 0665975224
First Name & Middle Initial & Last Name & Degree
Luca Weltert
First Name & Middle Initial & Last Name & Degree
Gianpiero Italiano
Facility Name
Hospital del Vinalopó
City
Alicante
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jose Albors Martin
First Name & Middle Initial & Last Name & Degree
Edgardo Castillo
First Name & Middle Initial & Last Name & Degree
Daniel Nuñez
First Name & Middle Initial & Last Name & Degree
Beatriz Miralles

12. IPD Sharing Statement

Learn more about this trial

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial

We'll reach out to this number within 24 hrs